🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Bare Anatomy parent Innovist crosses Rs 300 Cr revenue in FY25, turns profitable

EntrackrEntrackr · 3m ago
Bare Anatomy parent Innovist crosses Rs 300 Cr revenue in FY25, turns profitable
Medial

Innovist, the parent company of Bare Anatomy, Chemist at Play, Sunscoop, and Vinci, reported strong financial performance in the fiscal year ended March 2025, with total revenue surpassing Rs 300 crore while turning profitable during the year. Innovist has posted over 2.8X year-on-year growth in its operating revenue to Rs 299 crore in FY25 from Rs 105.8 crore in FY24, according to its consolidated financial statements filed with the Registrar of Companies (RoC). Founded in 2018 by Rohit Chawla, Sifat Khurana, and Vimal Bhola, Innovist, formerly known as Onesto Labs, offers hair and skin products and currently operates four brands: Bare Anatomy, Chemist at Play, Sunscoop, and Vinci Botanicals. The sale of these products was the primary source of revenue for the company, accounting for 97.5% of total revenue or Rs 291.5 crore, while the remaining Rs 7.6 crore came from the shipping receipts. Innovist also earned Rs 2.34 crore from interest on current investments and other non-operating sources, taking its total income to Rs 301.4 crore. On the expense side, advertising remained the company’s largest cost head, rising 2.5X year-on-year to Rs 136.5 crore and accounting for over 45% of the total expenditure. The cost of materials, another key expense component, also surged 2.6X to Rs 78.5 crore during the year. Warehousing-related expenses nearly tripled during the fiscal year to Rs 24 crore, while employee benefit expenses stood at Rs 15 crore, accounting for just 5% of the total cost. Meanwhile, commission paid to sole buying agents for procuring raw materials surged over 19X to Rs 15.5 crore. Other overheads, including transportation, rent, IT expenses, and legal and professional fees, took total expenses to Rs 301 crore in FY25. The D2C house of brands recorded nearly threefold revenue growth in the previous fiscal. It also booked Rs 11.8 crore in deferred tax income. Together, these helped the company turn profitable, posting a Rs 12 crore profit compared to a Rs 12.5 crore loss in FY24. Its ROCE improved to -1.46%, while the EBITDA margin turned positive at 0.42% in FY25 with an EBITDA of Rs 1 crore. On a unit level, Innovist improved its expense-to-earning ratio to Rs 1.01 during the period. The Gurugram-based company reported current assets of Rs 116 crore, including cash and bank balances of Rs 46 crore, as of March 2025. According to startup data intelligence platform TheKredible, the Gurugram-based company has raised $30 million in funding to date, including a $16 million round in April this year through a mix of primary and secondary transactions led by ICICI Venture, which also provided an exit to its existing backer Accel. After a difficult 2024 for the D2C category, some of which is still unfolding for some, many others who survived seem to have learned some important lessons. While the high advertising expenses don’t indicate a drop in competitive intensity yet, the topline growth does point to a business with a more than foothold in the market now. A funding revival of sorts is also underway with some recent news in the category, but for Innovist, bigger prizes await if it can sustain the growth and keep improving margins steadily.

Related News

Innovist raises Rs 136 Cr led by ICICI Venture; Accel exits

EntrackrEntrackr · 12m ago
Innovist raises Rs 136 Cr led by ICICI Venture; Accel exits
Medial

Innovist, the parent company of Bare Anatomy, has raised Rs 136 crore (approximately $16 million) in a Series B funding round led by ICICI Venture. The round saw participation from Mirabilis Investment Trust, Niveshaay Investment, and existing backer Sauce. The funding round includes both primary and secondary components and will be directed toward product development, business growth, and team expansion, the company said in a media release. In the round, the company provided exit to Accel, which came in via their seed program (atoms). Rohit Chawla, founder and CEO, said that Innovist is one of the fastest-growing BPC (beauty and personal care) firms in the country and aims to cross Rs 300 crore in revenue by FY25. While the company has not yet filed its annual statements for FY24, it reported operational revenue of Rs 36.53 crore in FY23, along with a loss of Rs 16.87 crore. Innovist, previously known as Onesto Labs, was founded in 2018 by Chawla, Sifat Khurana, and Vimal Bhola. The company provides personal care products and currently manages three brands: Bare Anatomy, Chemist at Play, and Sunscoop. To date, Innovist has raised over $26 million, including a $7 million Series A round led by the Amazon Smbhav Venture Fund. According to startup data platform TheKredible, prior to this round, Sauce.VC was the largest external stakeholder, followed by 72 Ventures, Accel India, and the Amazon Smbhav Fund. It competes with D2C beauty brands like Minimalist, Mamaearth, Wow Skin Science, and Sugar Cosmetics.

Exotel turns profitable in FY25; total income crosses Rs 500 Cr

EntrackrEntrackr · 2m ago
Exotel turns profitable in FY25; total income crosses Rs 500 Cr
Medial

Exotel turns profitable in FY25; total income crosses Rs 500 Cr The last fiscal year proved to be a milestone for Exotel as the cloud communication platform crossed the Rs 500 crore revenue mark in FY25 and also turned profitable, supported with controlled expenses and steady growth in its operating revenue. Exotel’s operating revenue increased by 10% to Rs 490.5 crore in FY25 from Rs 444.5 crore in FY24, according to its consolidated financial statements sourced from the Registrar of Companies (RoC). Exotel provides cloud-based voice and SMS contact center solutions, enabling businesses to manage customer engagement efficiently. Its primary revenue stream comes from offering internet-enabled cloud communication services. The bulk of the company’s revenue came from domestic services, which grew 9.5% to Rs 416 crore in FY25, while export services revenue rose 16% to Rs 74 crore. Including other income of Rs 16.5 crore, the company’s total income rose to Rs 507 crore in FY25 from Rs 460 crore a year earlier. On the cost side, Telephone and postage costs remained the largest expense, accounting for 44% of total costs. To the tune of scale, this expense increased 9% to Rs 212 crore in FY25 from Rs 195 crore in FY24. Employee benefit expenses, the second-largest cost head, declined by 21% to Rs 147 crore. Advertising and legal costs rose to Rs 12.5 crore and Rs 10 crore, respectively. Other expenses added the rest of Rs 77.5 crore. Overall, Exotel managed to bring down its total expenses by 4% to Rs 481 crore in FY25 from Rs 499 crore in FY24. The moderation in expenses and the steady revenue helped Exotel achieve profitability in the last fiscal year. The company posted a profit of Rs 20 crore in FY25, as compared to a loss of Rs 37 crore in FY24. Its ROCE and EBITDA margin improved to 2.46% and 6.83%, respectively. On a unit basis, Exotel spent Rs 0.98 to earn a rupee during the fiscal year, an improvement from Rs 1.12 in the previous year. As of March 2025, Exotel reported cash and bank balances of Rs 131 crore, while its current assets stood at Rs 290 crore. According to TheKredible, Exotel has raised $100 million of funding to date across multiple funding rounds, and counts Blume Ventures, A91 Partners, and Sistema Asia among its backers. According to the startup data intelligence platform TheKredible, A91 Partners is the largest external stakeholder with a 25.7% stake, followed by Blume Ventures. However, despite turning profitable in FY25, Exotel has witnessed notable leadership churn. Since late 2024, the company has seen the exit of several senior executives, including co-founder and COO Ishwar Sridharan.

L’Oréal in talks to acquire Bare Anatomy parent Innovist: Report

EntrackrEntrackr · 14d ago
L’Oréal in talks to acquire Bare Anatomy parent Innovist: Report
Medial

L’Oréal in talks to acquire Bare Anatomy parent Innovist: Report French beauty and cosmetics major L’Oréal is in advanced discussions to acquire a majority stake in direct-to-consumer (D2C) personal care startup Innovist, according to a Moneycontrol report. Innovist operates brands such as Bare Anatomy, Chemist at Play, Sunscoop, and Vinci Botanicals. According to the report, the proposed deal is expected to value Innovist between $350 million and $450 million (Rs 3,240–4,170 crore). The move comes as L’Oréal looks to strengthen its position in India. The report added that L’Oréal is expected to initially acquire a controlling stake in Innovist, followed by a gradual increase in ownership to 100% over the next few years. The D2C beauty and wellness space in India has witnessed a wave of strategic acquisitions and consolidation over the past few years, as large FMCG companies look to tap into digitally native brands with strong consumer recall. Recently, Hindustan Unilever Limited acquired the remaining 49% stake in Oziva for Rs 824 crore, following its earlier investments. Last month, pharmaceutical major USV acquired a 79% stake in Wellbeing Nutrition. During the same month, Mumbai-based consumer goods major Marico acquired a 60% stake in plant-based protein startup Cosmix at an equity valuation of Rs 375 crore. The trend builds on last year’s consolidation, which included HUL’s acquisition of skincare brand Minimalist at a pre-money valuation of Rs 2,955 crore. If completed at the aforementioned valuation, the L’Oréal–Innovist deal will surpass the HUL–Minimalist deal in size.

Exclusive: Bare Anatomy parent Innovist kicks off Series B round

EntrackrEntrackr · 1y ago
Exclusive: Bare Anatomy parent Innovist kicks off Series B round
Medial

Innovist, the parent company of Bare Anatomy, Chemist at Play, and Sunscoop, is raising Rs 49.25 crore (approximately $5.7 million) in its Series B round. This marks the first round of investment for the Gurugram-based company in 2025. The board at Innovist has passed a special resolution to issue 72,223 Series B compulsory convertible preference shares at an issue price of Rs 6,819 each, raising Rs 49.25 crore, according to its regulatory filing accessed from the Registrar of Companies (RoC). IVen Amplifi Fund (managed by ICICI Ventures Fund) will lead the round with Rs 19.47 crore, while Mirabilis Investment Trust will contribute Rs 10.1 crore. Sauce.VC and Niveshaay Sambhav Fund will also participate, investing Rs 8.75 crore and Rs 10 crore, respectively. The fresh proceeds will be utilized for recruitment, operations, sales, marketing, and other general corporate purposes, as decided by the board. According to Entrackr estimates, the company will be valued at approximately $140 million post-allotment. This capital infusion appears to be part of a larger funding round, with the potential for additional investments that could further impact its valuation. Founded in 2018 by Rohit Chawla, Sifat Khurana, and Vimal Bhola, Innovist—formerly known as Onesto Labs—offers personal care products. It currently operates three brands: Bare Anatomy, Chemist at Play, and Sunscoop. Innovist has raised over $16 million to date, including a $7 million Series A round led by the Amazon Smbhav Venture Fund. According to the startup data intelligence platform TheKredible, prior to this round, Sauce.VC was the largest external stakeholder, followed by 72 Ventures, Accel India, and the Amazon Smbhav Fund. The company has not yet filed its annual statements for the previous fiscal year (FY24). In FY23, it reported operational revenue of Rs 36.53 crore, while its losses amounted to Rs 16.87 crore during the same period.

Exclusive: BigHaat crosses Rs 1,100 Cr revenue in FY25; turns EBITDA profitable

EntrackrEntrackr · 7m ago
Exclusive: BigHaat crosses Rs 1,100 Cr revenue in FY25; turns EBITDA profitable
Medial

Exclusive All Stories Exclusive: BigHaat crosses Rs 1,100 Cr revenue in FY25; turns EBITDA profitable Full-stack agritech platform BigHaat Agro posted a flat scale with single-digit year-on-year growth in the fiscal year ending March 2025. However, the Bengaluru-based company managed to narrow its losses by over 25% during the last fiscal year. According to its co-founder Sateesh Nukala, BigHaat has crossed the Rs 1,100 crore revenue threshold in FY25 from Rs 1,050 crore in FY24. BigHaat’s revenue split consists of 85% of revenue coming from farm produce sales, with agri-inputs, which is direct to farmers, and digital only contributing 15%. The platform now counts 3 million monthly active farmers and reported 15% gross margins in FY25, said Nukala in an interaction with Entrackr. Nukala highlighted that exports and advanced processing, a high-margin vertical launched in FY25, now contribute 20% to its monthly revenue. “We have reduced our net loss to Rs 25 crore in FY25 from Rs 35 crore in FY24 and turned EBITDA positive for the last three quarters,” said Nukala. He also added that BigHaat is among the few agritech startups to achieve profitability at scale with 6x revenue-to-capital efficiency. As per Nukala, the company is targeting Rs 1,400 crore in FY26, with spices emerging as a key growth driver. “We are also open to acquisitions of new brands to strengthen our portfolio,” he emphasized. BigHaat has raised around $25 million to date. In January 2022, it raised Rs 100 crore led by JM Financial. Beyond Next Ventures, Ashish Kacholia, Ankur Capital, and others are some notable investors for the firm. This contrasts with larger peers. DeHaat, India’s most valued agritech startup, clocked Rs 2,675 crore revenue in FY24 but with losses of over Rs 240 crore. Ninjacart, backed by Walmart and Flipkart, crossed Rs 2,000 crore revenue in the same fiscal but recorded a Rs 259.6 crore loss. By combining steady topline growth, improving margins, and sustained EBITDA profitability, BigHaat is positioning itself as one of the few agritech ventures balancing scale with financial discipline, while many peers continue to burn capital at larger scales.

Amagi posts Rs 705 Cr revenue in H1 FY26; turns profitable

EntrackrEntrackr · 2m ago
Amagi posts Rs 705 Cr revenue in H1 FY26; turns profitable
Medial

Fintrackr All Stories Amagi posts Rs 705 Cr revenue in H1 FY26; turns profitable Bengaluru-based SaaS firm Amagi's financials show that the company turned profitable in the first half of FY26, aided by strong revenue growth and improving cost efficiency. Amagi’s operating revenue grew 34.5% to Rs 705 crore in H1 FY26 from Rs 524 crore in H1 FY25, according to its financial statements included in the Red herring prospectus (RHP). The company derives the bulk of its revenue from distribution and payout services, which contributed nearly 98% of operating revenue. Income from this segment rose 36% to Rs 690 crore during the period. Revenue from AdPlus remained largely flat at Rs 15 crore. Including other income of Rs 29 crore, Amagi’s total income increased to Rs 734 crore in H1 FY26 from Rs 551 crore in H1 FY25. Employee benefit expenses, the largest cost component, rose 12.5% to Rs 386 crore and accounted for over 53% of total expenditure. Communication costs increased 32.5% to Rs 216 crore, forming nearly 30% of overall expenses. Other overheads such as legal and professional charges declined to Rs 27 crore, while travel and other expenses together added Rs 71 crore during the period. Overall, total expenses increased at a slower pace of 18.2% to Rs 722 crore in H1 FY26 from Rs 611 crore in H1 FY25. With Amagi’s revenue outpacing the expense growth, it turned profitable in the first half of FY26 and posted a profit of Rs 6.5 crore in H1 FY26, as compared to a loss of Rs 66 crore in H1 FY25. As of September 2025, the Bengaluru-based firm reported cash and bank balances of Rs 397 crore, while its current assets stood at Rs 1,177 crore.

Download the medial app to read full posts, comements and news.